Transition Bio

Executive Summary

Transition Bio is a private UK-based biotech company founded in 2020 that is pioneering an end-to-end drug discovery platform centered on biomolecular condensates. By combining technologies from Harvard’s Weitz Lab and Cambridge’s Knowles Lab, the company leverages AI and proteomics to target previously undruggable proteins through modulation of phase separation. The platform integrates molecular-level insights with machine learning to identify and validate condensate-modulating compounds. Transition Bio aims to redefine drug discovery by addressing diseases driven by condensate dysfunction, including neurodegenerative and oncology indications. Despite being early-stage, the company's unique approach and strong academic roots position it as a potential leader in the emerging condensate therapeutics space. Key upcoming milestones include raising Series A financing, advancing its lead program to preclinical candidate nomination, and establishing strategic partnerships with large pharma.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement70% success
• Q4 2026Lead Program Preclinical Candidate Nomination50% success
• Q2 2027Pharma Partnership or Collaboration Deal40% success